Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761618 · ClinicalTrials.gov registry record · Phase 2
Intrapleural Catheter Daily Versus Three Times a Week Drainage
A Phase 2 study of Advanced Cancer and Pleural Effusion, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 257
- Enrollment target
- 1
- Study location
NCT00761618 is a Phase 2 study of Advanced Cancer and Pleural Effusion that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 257 participants, roughly in line with the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00761618, a Phase 2 study of Advanced Cancer and Pleural Effusion, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 257 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.
Conditions Studied
Interventions
- PROCEDURE Intrapleural catheter (IPC) drained
- PROCEDURE IPC Placement
- RADIATION Chest X-Ray
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2008-08-22 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761618
The ClinicalTrials.gov registry entry for NCT00761618 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 3 interventions - of which Intrapleural catheter (IPC) drained is the first listed.
NCT00761618 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00761618 about?
NCT00761618 is a clinical study titled "Intrapleural Catheter Daily Versus Three Times a Week Drainage". The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.
What is the current status of trial NCT00761618?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 257 participants. The study started on 2008-08-22. Estimated completion is 2026-08-31.
What conditions does trial NCT00761618 study?
This clinical trial studies the following conditions: Advanced Cancer, Pleural Effusion.
What interventions are being tested in trial NCT00761618?
The interventions under investigation include: Intrapleural catheter (IPC) drained (PROCEDURE), IPC Placement (PROCEDURE), Chest X-Ray (RADIATION).
Who is sponsoring clinical trial NCT00761618?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00761618 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.